PharmaCyte Biotech, Inc.
PMCB
$1.04
$0.032.97%
NASDAQ
| 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -1.13M | 30.66M | 20.25M | 22.68M | 26.94M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -3.75M | -34.99M | -22.71M | -24.52M | -29.60M |
| Change in Net Operating Assets | 275.90K | 1.36M | 185.70K | -100.80K | -206.10K |
| Cash from Operations | -4.60M | -2.98M | -2.27M | -1.94M | -2.87M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 0.00 | -7.00M | -7.00M | -12.00M | -12.00M |
| Cash from Investing | 0.00 | -7.00M | -7.00M | -12.00M | -12.00M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | 0.00 | 0.00 | 0.00 |
| Repurchase of Common Stock | -1.80M | -2.54M | -3.55M | -3.72M | -2.48M |
| Issuance of Preferred Stock | -- | -- | 0.00 | 0.00 | 0.00 |
| Repurchase of Preferred Stock | -13.06M | -22.49M | -32.01M | -34.93M | -26.94M |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 2.26M |
| Cash from Financing | -14.86M | -25.03M | -35.55M | -38.65M | -27.16M |
| Foreign Exchange rate Adjustments | -400.00 | -300.00 | -1.30K | 1.00K | -700.00 |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -19.46M | -35.01M | -44.83M | -52.59M | -42.03M |